JAN (NYSE:JAN) Upgraded by Compass Point to “Hold” Rating

JAN (NYSE:JAN) was upgraded by equities researchers at Compass Point to a “hold” rating in a note issued to investors on Wednesday, Zacks reports.

A number of other equities analysts also recently weighed in on JAN. Wall Street Zen raised shares of JAN from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings started coverage on JAN in a research report on Thursday, August 6th. They issued a “hold (c-)” rating on the stock. Jefferies Financial Group started coverage on JAN in a research report on Tuesday. They set a “buy” rating and a $36.00 price target for the company. Raymond James Financial initiated coverage on JAN in a report on Tuesday, June 16th. They set a “strong-buy” rating and a $34.00 target price for the company. Finally, Royal Bank Of Canada raised their price target on shares of JAN from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.31.

JAN Trading Down 3.4%

Shares of NYSE:JAN opened at $30.52 on Wednesday. The stock has a 50-day simple moving average of $30.48. JAN has a 12-month low of $22.76 and a 12-month high of $32.83.

JAN (NYSE:JAN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The firm had revenue of $216.46 million for the quarter, compared to the consensus estimate of $203.32 million. JAN’s quarterly revenue was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Sell-side analysts expect that JAN will post 0.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in JAN. WINTON GROUP Ltd acquired a new stake in JAN during the 2nd quarter valued at $2,985,000. Engineers Gate Manager LP purchased a new position in JAN in the 2nd quarter valued at about $15,274,000. Greenland Capital Management LP acquired a new stake in shares of JAN during the second quarter valued at about $575,000. Readystate Asset Management LP purchased a new stake in shares of JAN during the second quarter worth about $1,724,000. Finally, Wellington Management Group LLP purchased a new stake in shares of JAN during the second quarter worth about $8,739,000. 6.27% of the stock is owned by institutional investors and hedge funds.

JAN News Summary

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Monthly dividend provides income support: JAN declared a monthly dividend of $0.0475 per share, equivalent to an annualized yield of approximately 1.8%. The upcoming payments are scheduled for October 28, November 23, and December 29, 2026. JAN dividend announcement
• Positive Sentiment: Revenue growth remains strong: JAN reported quarterly revenue of $216.46 million, up 45.4% year over year and above the $203.32 million analyst consensus. Full-year fiscal 2026 guidance calls for earnings per share of $0.95 to $0.98.
• Neutral Sentiment: Analyst target indicates limited near-term upside: Analysts assign JAN an average price target of $31.71, modestly above the recent trading level. This suggests some potential upside, but not a major revaluation catalyst. JAN receives average analyst price target
• Negative Sentiment: Latest earnings missed expectations: JAN reported earnings of $0.05 per share, falling short of the $0.23 consensus estimate by $0.18. The earnings miss is likely the most important pressure on the stock, despite the better-than-expected revenue and continued growth.
• Negative Sentiment: Upside is being weighed against execution risk: With shares trading near the 50-day moving average and the analyst target only modestly higher, investors may remain cautious until JAN demonstrates that it can convert its revenue growth into stronger profitability.

About JAN

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.